Back

How I Treat: Precision Sequencing for EGFR-Mutated NSCLC and Exon 20 Insertion

How I Treat: Precision Sequencing for EGFR-Mutated NSCLC and Exon 20 Insertion

Zofia Piotrowska, MD, MHS, and Lyudmila Bazhenova, MD, FASCO, discuss molecular testing, treatment sequencing, and adverse event monitoring in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer, focusing on acquired MET-driven resistance after frontline osimertinib and EGFR exon 20 insertion disease that progresses after chemotherapy plus amivantamab.

How I Treat: Precision Sequencing for EGFR-Mutated NSCLC and Exon 20 Insertion

Episodes

All
All

Please check back later for more content.